Rigel Pharmaceuticals reported $250K in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Agenus AGEN:US USD 308K 1.72M
Amgen AMGN:US USD 1.59B 78M
Anika Therapeutics ANIK:US USD 17.48M 2.69M
AstraZeneca AZN:LN USD 2.12B 214M
Astrazeneca AZN:US USD 2.12B 214M
Biomarin Pharmaceutical BMRN:US USD 116.29M 6.84M
Bristol Myers Squibb BMY:US USD 2.35B 324M
Daiichi Sankyo 4568:JP JPY 84.77B 9.97B
Eli Lilly And LLY:US USD 1.58B 148.6M
Halozyme Therapeutics HALO:US USD 47.32M 13.38M
Heron Therapeutics HRTX:US USD 14.72M 1.46M
Intrexon XON:US USD 1.58M 234K
Karyopharm Therapeutics KPTI:US USD 980K 41K
Ligand Pharmaceuticals LGND:US USD 14.15M 1.79M
MacroGenics MGNX:US USD 3.14M 741K
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Pfizer PFE:US USD 6.09B 2.58B
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Rigel Pharmaceuticals RIGL:US USD 250K 786K
Ultragenyx Pharmaceutical RARE:US USD 8.63M 361K
Veracyte VCYT:US USD 26.01M 978K